Juno Therapeutics and WuXi AppTec Announce New Company to Develop Novel Cell-Based Cancer Immunotherapies in China Juno Therapeutics and WuXi AppTec announced that they have started a new company in China. JW Biotechnology Co., Ltd’s mission is to build China’s leading cell therapy company by leveraging Juno’s world-class chimeric antigen receptor and T cell receptor technologies together with WuXi AppTec’s R&D and manufacturing platform and local expertise to develop novel cell-based immunotherapies for patients with hematologic and solidorgan cancers. [WuXi AppTec] Press Release Celgene and Juno Announce Celgene Exercised Option to Develop and Commercialize CD19-Directed Product Candidates Celgene Corporation and Juno Therapeutics, Inc. announced that Celgene exercised its option to develop and commercialize the Juno CD19 program outside North America and China. [Juno Therapeutics, Inc.] Press Release ERC Advanced Grant for Cancer Researcher from Vetmeduni Vienna Veronika Sexl of the Institute for Pharmacology and Toxicology at Vetmeduni Vienna has been awarded a coveted ERC Advanced Grant from the European Research Council. The grant will provide funding of about € 2.5 million over the next five years for research into new possibilities of cancer therapy using the enzyme CDK6. [Vetmeduni Vienna] Press Release Helmsley Charitable Trust Awards $2.1 Million to Penn, Stanford and Seattle Children’s Research Institute to Explore Cell-Based Therapies for Type 1 Diabetes The Type 1 Diabetes (T1D) Program of The Leona M. and Harry B. Helmsley Charitable Trust has announced $2.1 million in grants to support research toward the creation of new T1D-specific cell therapies that could help delay or halt the progression of the disease. [The Leona M. and Harry B. Helmsley Charitable Trust] Press Release SELLAS Life Sciences Group Receives a Favorable Opinion for European Orphan Drug Designations for WT1 Cancer Vaccine (Galinpepimut-S) SELLAS Life Sciences Group announced that the Committee for Orphan Medicinal Products of the European Medicines Agency has rendered a favorable opinion as regards Orphan Drug Designation for the company’s WT1 cancer vaccine (galinpepimut-S) for the treatment of patients with acute myeloid leukemia and patients with malignant pleural mesothelioma. [SELLAS Life Sciences Group] Press Release BioLineRx Reports Successful Top-Line Results in Phase II Trial for AML BioLineRx announced positive top-line results from BL-8040’s Phase II clinical trial in relapsed or refractory acute myeloid leukemia (AML). The BL-8040 oncology platform is a short cyclic peptide that functions as a high-affinity antagonist for CXCR4, a chemokine receptor that is directly involved in tumor progression, angiogenesis, metastasis and cell survival. [BioLineRx] Press Release Type 1 Diabetes Cell Therapy Trial Enrolls First Patient at Sanford A clinical trial studying the body’s ability to type fight 1 diabetes using cell therapy has used the method on its first participant. “The Sanford Project: T-Rex Study” is a collaborative study between Sanford Health and Caladrius Biosciences, Inc., for adolescents with newly onset type 1 diabetes. [Sanford Health] Press Release Cynata Reports Compelling Results from Pre-Clinical Stem Cell Study in Graft-versus-Host Disease Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited, has received extremely positive interim data from a proof of concept study of its lead Cymerus mesenchymal stem cell product, CYP-001. [Cynata Therapeutics Limited] Press Release California Cryobank Stem Cell Services Acquires Southern Cord California Cryobank Stem Cell Services LLC. announced the recent acquisition of Southern Cord Inc., a cord blood bank primarily servicing the Southeastern region of the US. [California Cryobank Stem Cell Services LLC. (PR Newswire Association LLC.)] Press Release |